rIL-2 Immunotherapy for 19 Children with Advanced Metastatic Neuroblastoma
Considerable progress has been achieved in the treatment of stage IV neuroblastoma in children over 1 year of age. Induction therapy and surgery followed by vincristine, high-dose melphalan, total body irridiation, and autologous bone marrow transplantation (ABMT) enable the achievement of 40% progression-free survival at 2 years post-transplantation . However, late relapses occurring up to 72 months post-graft, with a projected disease- free survival at 5 years of only 20% to 25%, are a major concern. Therefore, new therapeutic approaches are needed; spontaneous regression of this tumor in children below 1 year of age favors a role of the immune system in antitumoral defense and the potential benefit of immunotherapy. However, since neuroblastoma cells lack class I and II major histocompatibility complex (MHC) antigens, any attempt to stimulate antitumoral defense should involve non-MHC-restricted immunity.
This work was supported by grant n°6245 from the Association pour la Recherche sur le Cancer, réseau INSERM LMCE n°48–60-22, and Comite de la Savoie of the Ligue Nationale contre le Cancer (grant RS-01()88).
KeywordsToxicity Catheter Albumin Dopamine Creatinin
Unable to display preview. Download preview PDF.
- 2.Favrot M, Floret D, Michon J et al. (1989) A phase II study of adoptive immunotherapy with continuous infusion of Interleukin 2 in children with advanced neuroblastoma. Cancer Treat Rev 16, suppl A:129–142Google Scholar
- 4.Coze C, Combaret V, Philip I et al. Analysis of parameters for maximal in vitro proliferation and activation of lymphokine-activated killer cells (LAK). Nouv Rev Fr Hematol; 31:339–343Google Scholar
- 5.Philip T, Helson L, Bernard JL, Zucker JM, Kremens B, Favrot MD, Hartman O (1987) Definition of response and remission in children over one year of age with an advanced neuroblastoma:Proposition for a scoring system. Ped Hemat Oncol 4:25–31Google Scholar
- 8.Philip T, Mercatello A, Negrier S et al. (1989) Interleukin 2 with or without LAK cells in metastatic renal cell carcinoma:the Lyon first year experience on 20 patients. Cancer treat Rev 16, suppl A:91–104Google Scholar